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to IA management with voriconazol (VCZ) versus amphotericin B (ANB), and 
liposomal amphotericin B (LAB) from private and public payer’s perspectives in 
Brazil. Methods: IA treatment was simulated in a decision-tree model with VCZ 
(6mg/kg twice, followed by 4mg/kg bid, 10 days), ANB (1.5mg/kg/day, 13 days), and 
LAB (3mg/kg/day, 13 days) and their associated costs in a 12-week time horizon. After 
first evaluation, responders continued with maintenance treatment and those with 
failure switched to a second treatment (caspofungin was also considered as rescue 
therapy). Efficacy data (clinical response), adverse events, and mortality rate were 
generated by meta-analysis based on systematic literature review. Costs included 
drugs, medical follow-up and adverse events management, collected from Brazilian 
private and public official databases (values represented 2013 BRL). Results: 
Clinical response and mortality rate in 12 weeks were [56.67%; 34.1%], [36.42%; 
50.9%], and [34.56%; 48.7%] for VCZ, ANB, and LAB, respectively. Total treatment costs 
with VCZ, ANB, and LAB were 40,635.71BRL, 18,570.14BRL and 86,646.42BRL from 
private, and 25,152.81BRL, 3,751.90BRL, and 62,107.87BRL from the public perspec-
tive, respectively. VCZ presented the highest response rate and lower mortality rate 
at 12 weeks. ANB was the least costly followed by VCZ. VCZ presented an economy 
of 46,010.71BRL and 36,955.07BRL when compared to LAB, from private and public 
perspectives, respectively. Main cost driver was related to drug acquisition (VCZ and 
LAB groups), and daily in ICU (ANB group). ConClusions: In this analysis, VCZ in 
IA treatment presented the greatest clinical response and the lower mortality rate 
when compared to ANB and LAB. Total treatment cost was higher than ANB but 
lower when compared to LAB in Brazilian private and public health care systems.
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objeCtives: Neglected diseases (ND) are a group of illness caused by infectious 
and parasitic agents endemic in low-income populations. ND control is essential for 
achieving country development and inequalities reduction. The Brazilian Program 
for Research and Development in Neglected Diseases (BPRDND) was created by the 
Brazilian Ministry of Health. Seven priorities were established: dengue, Chagas dis-
ease, leishmaniasis, hanseniasis, malaria, schistosomiasis and tuberculosis. This 
study aims to evaluate hospitalization patterns and costs related to those diseases 
after BPRDND implementation. Methods: Analysis of reported ND related hos-
pital admissions was developed according to ICD-10 classification as described in 
Brazilian Hospital Information System (SIH/SUS) database, from January 2009 to 
December 2011. Only seven priority diseases were included. Costs represent federal 
reimbursement values for hospitalizations (medical procedures, exams, drugs and 
fees) estimated in 2014 Brazilian Real (BRL). Results: From 2009 to 2011, 306,682 
hospitalizations due to all selected ND were observed and dengue represented 70.22% 
of all. Dengue treatment was responsible for 69.58% of ND related procedures. Total 
cost was 162,458,715BRL in the period with 46.22% and 41.78% due to tuberculosis 
and dengue, respectively. Over the years, cost distribution was: 16,039,294BRL in 2009, 
27,970,785BRL in 2010, and 23,869,733BRL in 2011 for dengue, and 21,791,027BRL in 
2009, 23,889,130BRL in 2010 and 29,410,353BRL in 2011 for tuberculosis. Compared 
to 2009, 2011 showed an increase of 39% and 37% in hospitalizations and associated 
costs, respectively. In-hospital deaths presented an increase of 9.7%, except for Chagas 
disease and schistosomiasis, with reduction of 45% and 56%, respectively. Geographic 
distribution indicated northeast region accounting for 39.47% of hospital admissions, 
and 35.72% of costs, followed by southeast (23.02% and 29.79%, respectively) and north 
region (20.02% and 13%, respectively). ConClusions: Despite the implementation of 
PRDND in Brazil, this class of diseases still presents high frequency of hospitalization 
and costs, specially dengue and tuberculosis.
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objeCtives: To evaluate the economic impact of herpes zoster (HZ) on the US 
health care system among immunocompetent persons. Methods: Administrative 
claims from the Truven Health MarketScan® Research Databases (2008-2011) were 
assessed to determine the incremental medical resource utilization (RU) and cost 
associated with herpes zoster. Cases were selected based on an ICD-9-CM diagno-
sis code for HZ (ICD-9-CM 053.xx), continuous enrollment 12 months pre/post the 
earliest diagnosis (‘index’), and having no HZ diagnosis or evidence of receiving 
the Zostavax® vaccine in the 12 months pre-index. Cases were direct matched 1:1 
using demographic and clinical variables to immunocompetent controls without 
HZ. Analysis of potentially HZ-related RU and costs was limited to claims 21 days 
prior to through the first year following HZ diagnosis. Cases with postherpetic neu-
ralgia (PHN) were examined separately. Results: Data were from 98,916 cases and 
controls: 56.6% female, mean age 50.45 (standard deviation (SD) 18.83) years. The 
majority of PHN cases (n= 2,405) were female (64.2%), mean age 61.74 (SD= 16.73) 
years. HZ cases had significantly more RU in all categories (inpatient admissions, 
emergency room visits, office visits and number of other outpatient services) com-
pared to controls (p < 0.001) and those differences increased substantially in the 
presence of PHN. The total mean incremental health care costs for HZ cases were 
$1,308 which more than quadruple when PHN is present ($5,463), (both p< 0.001). 
For all cases, the primary cost drivers were outpatient prescriptions and other out-
patient services (e.g., laboratory, radiology), but for patients with the added burden 
of PHN, inpatient services also played a significant role. ConClusions: Herpes 
zoster is a significant economic and resource burden on the US health care system 
among the immunocompetent which grows exponentially when complicated by 
PHN. Further emphasis on vaccination against HZ should be considered to help 
alleviate this medical burden.
that of patients infected with carbapenem-sensitive bacteria. Methods: A cross 
sectional study was carried out for 3 months and the data for hospitalization cost 
was collected for the patients with carbapenem resistant and carbapenem sensi-
tive infections from the medicine ICU and the microbiology department for 114 
patients with bacterial infections who were admitted to Intensive care unit. The 
data was analyzed for the type of infection and the average hospitalization cost. The 
median hospitalization cost was calculated for both the group of patients. Results: 
Out of 247 patients admitted in the ICU during a three month period 70(28.34%) 
were found to be having carbapenem-resistant infections and 44(17.81%) were 
found to have carbapenem-sensitive infections. The median length of stay in the 
hospital was 9 days for carbapenem-sensitive patients while 23.5 days in case of 
carbapenem-resistant patients. The median hospitalization cost was found to be 
40185 INR in case of carbapenem sensitive patients while it was 126889.5 INR in 
case of carbapenem-resistant patients. ConClusions: Carbapenem-resistance is 
observed to be increasing the morbidity and cost burden on the patients substan-
tially. Increased length of hospital stay leads to an increase in the incidence of 
Nosocomial infections which further leads to the increased morbidity, mortality 
and cost burden on the society.
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objeCtives: Studies has shown that receiving 23-valent pneumococcal polysac-
charide vaccines (PPV23) would reduce the risk of pneumonia-related diseases 
and death for the elderly but the economic benefit of receiving PPV23 is unknown. 
This study aims to evaluate the economic benefit of PPV23 for the elderly aged 75 
years and above in Taiwan. Methods: The outcome data was drawn form Taiwan’s 
National Health Insurance Research Database and immunization information was 
derived from the National Immunization Information System (NIIS). PPV23 were 
provided to a total of 318,257 citizens who were free of PPV23 during 2007-2008 and 
the vaccination coverage rate was about 24.5% for the elderly population. Their 
1-year total medical cost (outpatient and inpatient) and 1-year pneumonia-related 
cost were recorded after they were vaccinated. A propensity score matching is used 
to avoid the selection bias due to the systematic difference between the vaccinated 
group and non-vaccinated group, and then GEE regression models were used to 
estimate the difference of the costs between two groups. Results: After controlling 
the demographic characteristics, medical history and medical utilization, 1-year 
total medical cost and 1-year pneumonia-related cost for the vaccinated group 
compared with the non-vaccinated group had significant reductions of 94.45 USD 
(p-value < 0.0001) and 86.77 USD (p-value < 0.0001), respectively. On average, the 
cost-saving of the vaccination for the elderly was 2.75 million USD. ConClusions: 
PPV vaccination can provide not only clinical benefit but also economic benefit and 
we believed that the economic benefit was underestimated because the herd effect 
was not taken into account.
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objeCtives: Nosocomial pneumonia (NP) is the second most common cause of 
in-hospital infection and the leading cause of death from infections acquired in 
hospitals commonly caused by methicillin resistant Staphylococcus aureus (MRSA). 
This study aims to evaluate clinical and economic outcomes related to NP treat-
ment with linezolid versus teicoplanin and vancomycin from a private and pub-
lic payer’s perspectives in Brazil. Methods: A decision-tree model simulates NP 
treatment with linezolid (600mg bid, 19 days), teicoplanin (400mg bid, 22 days), and 
vancomycin (15mg/kg bid, 24 days) and their associated costs in a time horizon of 
complete hospital care. After a first evaluation patients with response continued 
with maintenance treatment and those with failure switched to a second treat-
ment. Efficacy data (clinical response) was generated by meta-analysis based on 
systematic literature review. Costs included drugs, medical follow-up and adverse 
events management, collected from Brazil official databases (values represented 
2013 BRL). Results: Clinical response, days on ward, and intensive care unit (ICU) 
days were [72.6%; 7; 12], [68.3%; 8; 14], and [66.5%; 8; 16] for linezolid, teicoplanin, 
and vancomycin, respectively. Total treatment costs with linezolid, teicoplanin, and 
vancomycin were 49,426.43BRL, 79,710.87BRL and 81,352.99BRL from the private 
perspective and 15,213.60BRL, 13,884.51BRL, and 24,348.44BRL from the public per-
spective, respectively. Linezolid represented the least costly in private perspective 
(economy of 30,284BRL and 31,927BRL when compared to teicoplanin and vanco-
mycin). The main cost driver for all treatments was related to daily in ICU followed 
by adverse events management (teicoplanin and vancomycin) and drug acquisition 
(linezolid). ConClusions: In this analysis, linezolid in NP management presented 
the greatest clinical response, shorter hospital stay in ward and ICU, and lower price 
when compared to teicoplanin and vancomycin in Brazilian private health care 
system and lower price when compared to teicoplanin in public set.
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objeCtives: Invasive aspergillosis (IA) is a severe infection that usually affects 
immunosuppressed patients in intensive care units (ICU), with high morbidity 
and mortality rates. This study assesses clinical and economic outcomes related 
